SCHEMBL2523313

SCHEMBL2523313

CCCCC/C=C\C/C=C\CCCCCCCC(=O)Oc1ccc(C=Cc2cc(OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)cc(OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
CYP3A4 P08684 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
TTR P02766 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49
ALDH1A1 P00352 5/20 0.47
F7 P08709 3/20 0.47
F3 P13726 3/20 0.47
FABP3 P05413 3/20 0.47
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
ALOX15 P16050 2/20 0.47
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TDP1 Q9NUW8 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099328 0.98 KMT2A (0.51) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL2519160 0.98 KMT2A (0.51) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL4098725 0.96 MAPT (0.50) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL2515292 0.94 ALB (0.45) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL2518028 0.93 PSMB11 (0.48) KDM4ECYP3A4KMT2ALMNAMEN1
SCHEMBL2517222 0.93 ALDH1A1 (0.55) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL2518734 0.92 ALB (0.49) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL19873143 0.92 ALB (0.49) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL29761138 0.92 ALB (0.49) KDM4ECYP3A4KMT2ALMNASMN1; SMN2
SCHEMBL2516512 0.92 ALB (0.46) KDM4ECYP3A4KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9162083-B2 Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions ELC MANAGEMENT LLC (US) 2015-10-20 US claimed
US-20140127146-A1 Linoleic And Linolenic Acid Esters Of Resveratrol And Cosmetic Compositions MAES DANIEL H (US) 2014-05-08 US claimed
US-9861564-B2 Valeric acid esters of resveratrol and cosmetic compositions ELC MANAGEMENT, LLC (US) 2018-01-09 US disclosed
US-9782335-B2 Malic acid esters of resveratrol and cosmetic compositions ELC MANAGEMENT LLC (US) 2017-10-10 US disclosed
US-20160303016-A1 Valeric Acid Esters Of Resveratrol And Cosmetic Compositions ELC MAN LLC (US) 2016-10-20 US disclosed
EP-2445511-B1 SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS ELC MAN LLC (US) 2016-09-07 EP disclosed
US-20160229791-A1 Malic Acid Esters Of Resveratrol And Cosmetic Compositions ELC MAN LLC (US) 2016-08-11 US disclosed
US-9358194-B2 Succinic acid esters of resveratrol and cosmetic compositions ELC MANAGEMENT LLC (US) 2016-06-07 US disclosed
US-9295621-B2 Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant ELC MANAGEMENT LLC (US) 2016-03-29 US disclosed
US-20160038389-A1 Succinic Acid Esters Of Resveratrol And Cosmetic Compositions ELC MAN LLC (US) 2016-02-11 US disclosed
US-9180316-B2 Butyric acid esters of resveratrol and cosmetic compositions ELC MANAGEMENT LLC (US) 2015-11-10 US disclosed
EP-2185128-A1 COSMETIC COMPOSITIONS CONTAINING RESVERATROL DERIVATIVES ELC Management LLC (US) 2010-05-19 EP disclosed
US-20100080845-A1 Cosmetic Methods And Compositions For Repairing Human Skin MAES DANIEL H 2010-04-01 US disclosed
US-20090047309-A1 COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN ELC MANAGEMENT LLC 2009-02-19 US disclosed
US-20090035243-A1 Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035242-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone ELC MANAGEMENT LLC 2009-02-05 US disclosed
WO-2009017866-A1 COSMETIC COMPOSITIONS CONTAINING RESVERATROL DERIVATIVES ELC MANAGEMENT LLC (US) 2009-02-05 WO disclosed
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant ELC MANAGEMENT LLC 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035243-A1 Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives RB1, SIRT1, EP300 KDM4E 506/4885CYP3A4 3306/4885KMT2A 1048/4885
US-20090035242-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone SQLE, SMURF1, PIK3R1 KDM4E 1188/4885CYP3A4 3607/4885KMT2A 1326/4885
US-20090047309-A1 COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN CUTA, ERCC1, OGG1 KDM4E 1584/4885CYP3A4 1901/4885KMT2A 2496/4885
US-20160303016-A1 Valeric Acid Esters Of Resveratrol And Cosmetic Compositions CUTA, SUV39H1, RARA KDM4E 450/4885CYP3A4 272/4885KMT2A 1070/4885
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant SMURF1, CUTA, SMURF2 KDM4E 1074/4885CYP3A4 3939/4885KMT2A 1425/4885
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent CUTA, LRAT, RARA KDM4E 1813/4885CYP3A4 3477/4885KMT2A 1492/4885
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent SMARCC1, RARG, RARA KDM4E 2286/4885CYP3A4 3430/4885KMT2A 1387/4885
US-20100080845-A1 Cosmetic Methods And Compositions For Repairing Human Skin CUTA, ERCC1, OGG1 KDM4E 1584/4885CYP3A4 1901/4885KMT2A 2496/4885
US-20160229791-A1 Malic Acid Esters Of Resveratrol And Cosmetic Compositions ME1, ME2, ME3 KDM4E 421/4885CYP3A4 776/4885KMT2A 1214/4885
US-20160038389-A1 Succinic Acid Esters Of Resveratrol And Cosmetic Compositions SUCNR1, SIRT1, SUCLA2 KDM4E 368/4885CYP3A4 1000/4885KMT2A 1305/4885
US-20140127146-A1 Linoleic And Linolenic Acid Esters Of Resveratrol And Cosmetic Compositions LRAT, ELOVL1, ELOVL6 KDM4E 1522/4885CYP3A4 3020/4885KMT2A 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.